Walleye Trading’s RAPT Therapeutics RAPT Stock Holding History

Walleye Trading’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-513	Closed	-$127K	–	5774
2021 Q3	$127K	Buy	+513	New	+$136K	﹤0.01%	4229

Other funds holding RAPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Walleye Trading's RAPT Position: Q1 2023 in Review

Walleye Trading sold out of RAPT Therapeutics (RAPT) in Q1 2023, closing a stake of 1,577 shares — an estimated $250K sold.

Walleye Trading first reported a position in RAPT in Q3 2021 and held it in 2 quarters. The position peaked at $250K in Q4 2022. 106 funds tracked by Wall St. Rank hold RAPT as of Q1 2023.

Walleye Trading reported no remaining RAPT Therapeutics position as of Q1 2023 after selling out during the quarter.
Walleye Trading sold 1,577 RAPT Therapeutics shares in Q1 2023, an estimated $250K.
Walleye Trading first reported a position in RAPT Therapeutics in Q3 2021 and held it in 2 quarters.
Walleye Trading's RAPT Therapeutics position peaked at $250K in Q4 2022.
106 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2023.

Based on Walleye Trading's 13F filing for Q1 2023, filed 15 May 2023.